Pediatric Vaccine Global Market Report 2023

“Pediatric Vaccine Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pediatric vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pediatric vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The pediatric vaccine market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Vaccine Type: Monovalent; Multivalent

2) By Technology: Live Attenuated; Inactivated; Toxoid; Conjugate; Other Technologies

3) By Application: Infectious Disease; Allergy; Cancer

Companies Mentioned: GlaxoSmithKline plc; Pfizer Inc.; Sanofi S.A.; Merck & Co., Inc.; Indian Immunologicals Limited

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the pediatric vaccines market are: GlaxoSmithKline plc, Pfizer Inc., Sanofi S.A., Merck & Co., Inc., Indian Immunologicals Limited, AstraZeneca plc, CSL Limited, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India Pvt. Ltd., Panacea Biotec Ltd., Zydus Cadila, BIO-MED, Squibb, Novartis , Abbott Laboratries, Eli Lillyand Company, F. Hoffmann- La Roche Ltd., Novo Nordisk A/S, VF Corporation, Sinovac Biotech Ltd., Bristol- Myers, Sun Pharmaceutical Industries Ltd, Sellas and Takeda Pharmaceutical Company Limited, Daiichi Sankyo, Bristol- Myers and Sinovac Biotec Ltd.

The global pediatric vaccine market is expected to grow from $31.44 billion in 2021 to $36.64 billion in 2022 at a compound annual growth rate (CAGR) of 16.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services effecting many markets across the globe. The pediatric vaccine market is expected to reach $57.51 billion in 2026 at a CAGR of 11.9%.

The pediatric vaccines market consists of sales of BCG vaccines, hepatitis B vaccines, pentavalent vaccines, and rotavirus vaccines. Values in this market are: 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Pediatric vaccines refer to medications that are typically given to children as a form of protection against serious, frequently fatal diseases. They get the children's body ready to battle the disease more quickly and successfully by boosting its natural defences.

North America was the largest region in the pediatric vaccines market in 2022. Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the pediatric vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types of pediatric vaccines are monovalent and multivalent. A monovalent vaccine is made up of only one antigen strain. The technology used includes live attenuated, inactivated, toxoid, conjugate, and other technologies to provide immunity from infectious disease, allergy, and cancer.

The rising prevalence of chronic diseases such as tuberculosis, diphtheria, and pneumonia in the age group of 15 years and below will contribute to the growth of the pediatric vaccines market. The risk of severe disease outcomes and complications of infectious diseases are increasing in children and adolescents with chronic conditions. According to the World Health Organization, chronic disease prevalence rose by 57% in the year 2020. The increased prevalence of chronic diseases among children rises the demand for immunization from chronic diseases, hence, driving the pediatric vaccines market's growth.

Vaccine refusal by parents for their children is a prevailing tradition in many countries. Among the reasons for withholding children from vaccination are lack of knowledge, religious and philosophical objections, exaggerated concerns regarding vaccine safety, and others. According to a nationwide survey found that over half (51%) of pediatric services in the United States have a policy to dismiss families that refuse childhood vaccines. 37% of pediatricians themselves said they often dismissed families for refusing vaccines, and 6% said they would dismiss a family for choosing to reach out to crucial early vaccines. Governments are imposing laws and organizing awareness programs to overcome parents' and families' resistance to the child's vaccine, but are unable to impose any strict rules against parents' refusal of children's immunization, which may hinder the pediatric vaccines market's growth.

The demand for novel vaccines is steadily growing to deliver improved immunization against challenging infectious diseases (e.g. tuberculosis, HIV/ AIDS) and non-communicable chronic diseases such as cancer and neurodegenerative diseases. Novel approaches to vaccine development include structural immunogenic design, gene-based vaccine platforms, and effective adjuvant recombinant antigen formulations. To meet the increasing demand for novel vaccines, there is a continuous quest for pediatric vaccine manufacturers and developers for the innovation of vaccine design and manufacturing technologies. For instance, in January 2020, Hilleman laboratories, global research, and development organization, announced their plans to develop a novel vaccine against Group B Streptococcus, a major cause of neonatal infections in women, in the area of maternal and child health.

The countries covered in the pediatric vaccines market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified).

The revenues for a specified geography are consumption values - that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products.

The pediatric vaccines market research report is one of a series of new reports from The Business Research Company that provides pediatric vaccines market statistics, including pediatric vaccines industry global market size, regional shares, competitors with a pediatric vaccines market share, detailed pediatric vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the pediatric vaccines industry. This pediatric vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.